Financial Performance - The company's operating revenue for Q3 2024 was ¥181,524,998.96, a decrease of 18.99% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2024 was ¥11,828,133.46, down 41.44% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥11,455,276.64, a decline of 41.26% compared to the previous year[3]. - The basic earnings per share for Q3 2024 were ¥0.02, a decrease of 33.33% compared to the same period last year[3]. - The net profit for Q3 2024 was CNY 20,139,194.30, a decrease of 56.6% compared to CNY 46,438,288.71 in Q3 2023[15]. - Operating profit for Q3 2024 was CNY 26,435,003.77, down 44.5% from CNY 47,714,006.59 in the same period last year[15]. - Total revenue from operating activities was CNY 655,440,762.39, a decline of 20.6% compared to CNY 826,064,891.56 in Q3 2023[18]. - The total profit for Q3 2024 was CNY 25,171,154.91, a decrease of 47.8% from CNY 48,211,892.47 in Q3 2023[15]. Assets and Liabilities - The total assets at the end of Q3 2024 were ¥984,788,339.45, representing a decrease of 13.97% from the end of the previous year[3]. - The equity attributable to shareholders at the end of Q3 2024 was ¥683,874,554.35, down 15.07% from the end of the previous year[3]. - The total assets at the end of the period are ¥984,788,339.45, down from ¥1,144,706,388.58 at the beginning of the period, a decrease of 13.9%[12]. - The total liabilities amount to ¥275,473,511.60, down from ¥311,228,355.03, indicating a reduction of 11.5%[13]. Cash Flow and Expenses - The net cash flow from operating activities for the year-to-date was ¥66,637,544.70, a decrease of 27.47% compared to the same period last year[3]. - The company reported a net cash flow from operating activities of CNY 66,637,544.70, a decrease of 27.4% from CNY 91,875,569.97 in Q3 2023[18]. - Research and development expenses decreased to CNY 29,383,363.35, down 19.5% from CNY 36,523,429.87 in the previous year[15]. - Total sales expenses for Q3 2024 were CNY 302,748,648.37, a reduction of 23.5% compared to CNY 396,000,546.49 in Q3 2023[15]. Inventory and Receivables - Cash and cash equivalents at the end of the period are ¥327,460,207.48, down from ¥401,100,106.17 at the beginning of the period, indicating a decrease of 18.3%[11]. - Accounts receivable decreased to ¥64,229,988.83 from ¥79,482,613.10, a reduction of 19.2%[11]. - Inventory has decreased to ¥115,227,500.42 from ¥149,086,389.06, representing a decline of 22.7%[11]. - The cash and cash equivalents at the end of Q3 2024 were CNY 318,797,669.66, down from CNY 362,901,383.52 at the end of Q3 2023[19]. Government Support and Market Activity - The company received government subsidies amounting to ¥1,234,235.36 during the reporting period, contributing to its financial performance[4]. - The company has not reported any new product developments or market expansion strategies during this period[12]. Profitability Metrics - The weighted average return on net assets was 1.74%, down 0.80% year-on-year[3]. - The company incurred financial expenses of CNY -3,870,821.15, slightly higher than CNY -3,749,505.41 in the previous year[15].

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 395,153,676.21, a decrease of 19.73% compared to CNY 492,309,107.65 in the same period last year[11]. - The net profit attributable to shareholders of the listed company was CNY 11,081,494.83, down 70.21% from CNY 37,203,988.86 year-on-year[11]. - The net profit after deducting non-recurring gains and losses was CNY 9,828,742.56, a decline of 72.46% compared to CNY 35,689,954.82 in the previous year[11]. - The basic earnings per share decreased by 66.67% to CNY 0.02 from CNY 0.06 in the same period last year[11]. - The total assets at the end of the reporting period were CNY 999,613,345.78, a decrease of 12.68% from CNY 1,144,706,388.58 at the end of the previous year[11]. - The net assets attributable to shareholders of the listed company were CNY 672,046,420.89, down 16.54% from CNY 805,267,326.06 at the end of the previous year[11]. - The net cash flow from operating activities was CNY 54,584,107.85, a slight decrease of 2.40% compared to CNY 55,925,042.19 in the same period last year[11]. - The company reported a total profit for the reporting period of approximately ¥13.95 million, representing a decline of 55.60% year-on-year due to decreased profitability from the core product[89]. - The total comprehensive income for the first half of 2024 was ¥11,068,802.14, down from ¥29,992,166.43 in the first half of 2023, indicating a significant decline[169]. Market and Industry Trends - The pharmaceutical industry is a crucial part of the national economy, with a long-term strong demand driven by increasing healthcare needs due to rising living standards and an aging population[15]. - By the end of 2023, the number of people covered by basic medical insurance reached 1.333 billion, maintaining a coverage rate of over 95%[15]. - The per capita financial subsidy for residents' medical insurance increased from 200 RMB in 2011 to 670 RMB in 2024, a rise of 235% over 13 years[15]. - The population aged 60 and above reached 297 million by the end of 2023, accounting for 21.1% of the total population, indicating a significant increase in the aging demographic[16]. - Chronic non-communicable diseases have a prevalence rate of 23% in China, with these diseases accounting for 86% of total deaths, indicating a growing market for long-term medication and disease management[17]. Product Development and R&D - The company has established strong products in the fields of cardiovascular and skeletal diseases, which are expected to benefit from the dual factors of aging and chronic diseases[18]. - The company has a total of 162 drug approval numbers, including 15 exclusive products, with 93 products listed in the National Basic Medical Insurance Directory (2023 edition) and 43 products in the National Essential Medicines List (2018 edition)[26]. - The company has invested heavily in research for its key products, with over 400 academic papers published on Wohua® Xinkeshu Tablets, including 22 in SCI journals[32]. - The company has developed Bone Density Capsules/Granules, a Class B product under national medical insurance, which has shown significant efficacy in treating osteoporosis and has received 6 national invention patents[33]. - The company is focusing on expanding its market presence through new product launches and technological advancements[40]. Marketing and Sales Strategy - The company has implemented a comprehensive marketing strategy based on "one center and four basic points," continuously reforming its marketing system to adapt to market changes[25]. - The marketing system covers 14,583 grade hospitals, 24,252 chain and independent pharmacies, and 33,108 community health centers, enhancing market penetration and brand recognition[25]. - The company’s marketing strategy has shifted to a budget-based professional clinical promotion model, responding to significant price reductions of core products[59]. - The company has adopted a "full-service marketing" approach, prioritizing support for frontline sales personnel to enhance customer service[61]. - The company is exploring new online sales models in response to changing consumer habits, enhancing service to patient groups[48]. Financial Management and Investments - The company plans to leverage its four core exclusive medical insurance products to drive growth in other product lines and ensure sustainability[88]. - The company aims to conduct cautious mergers and acquisitions to enhance its product line and maintain a strong cash reserve[88]. - The company has received a warning and a fine of 500,000 yuan for failing to disclose information in a timely manner, as per the administrative penalty decision by the China Securities Regulatory Commission[131]. - The company has approved loans of up to 150 million RMB and 100 million RMB to the same subsidiary in previous shareholder meetings[138]. Environmental and Social Responsibility - The company is committed to environmental protection and has established a comprehensive waste management system[112]. - The company has implemented various environmental protection laws and standards, including the "Comprehensive Emission Standard of Wastewater" (GB8978-1996) and "Air Pollutants Emission Standard for Pharmaceutical Industry" (GB 37823-2019)[108]. - The company actively participated in public welfare activities, donating medicines to local communities and providing free patient education[124]. - The company organized various employee activities, including health management and training programs, to enhance employee well-being and development[125]. Corporate Governance - The company has established a flat organizational structure with a board of directors and an executive committee to facilitate quick decision-making and enhance operational efficiency[84]. - There were changes in the board of directors, with Wang Jiong elected as a director and Zhao Caixia resigning as the board secretary[104]. - The company has not engaged in any major related party transactions outside of the approved loans[138]. - The company has maintained its ability to continue as a going concern for at least 12 months from the reporting date[189].

山东沃华医药科技股份有限公司 2024 年半年度控股股东及其他关联方资金占用情况汇总表 编制单位：山东沃华医药科技股份有限公司 单位：元 | | 资金占用 | 占用方与上 | 上市公司核算 | 2024 年期初占 | 2024 年半年度占 | 2024 年半年 | 2024 年半年度 | 2024 年半年度期 | 占用形 | 占用性 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 方名称 | 市公司的关 | 的会计科目 | 用资金余额 | 用累计发生金额 | 度占用资金的 | 偿还累计发生额 | 末占用资金余额 | 成原因 | 质 | | | | 联关系 | | | （不含利息） | 利息（如有） | | | | | | 现大股东及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 前大股东及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 总计 | | | | | | ...

山东沃华医药科技股份有限公司 2024 年半年度财务报表 财务报表 1、合并资产负债表 编制单位：山东沃华医药科技股份有限公司 2024 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 314,982,248.77 | 401,100,106.17 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | | | | 衍生金融资产 | | | | 应收票据 | 2,752,784.85 | 3,288,588.46 | | 应收账款 | 63,007,027.87 | 79,482,613.10 | | 应收款项融资 | 5,253,604.78 | 16,434,454.26 | | 预付款项 | 3,597,615.12 | 2,206,886.28 | | 应收保费 | | | | 应收分保账款 | | | | 应收分保合同准备金 | | | | 其他应收款 | 15,374,604.64 | 14,341,595.95 | | 其中：应收利息 | | | | 应收股 ...

根据中国证监会山东监管局《行政处罚决定书》（〔2024〕1 号）和本所查明的事实，山东沃华医药科技股份有限公司（以下 简称公司）及相关当事人存在以下违规行为： 公司实际控制人、董事长赵丙贤因涉嫌职务违法犯罪，自 2023 年 7 月 13 日至 2023 年 11 月 21 日被阳新县监察委员会实施 留置，该留置措施对其履行职责有影响。阳新县监察委员会于 2023 年 7 月 13 日向公司副董事长兼时任董事会秘书赵彩霞送达 《留置通知书》和《立案通知书》，赵彩霞决定不披露赵丙贤被采 取留置措施。经督促，公司才于 2023 年 11 月 7 日披露《关于实 际控制人被留置的公告》，公司信息披露存在不及时的情形。 公司的上述行为违反了本所《股票上市规则（2023 年修订）》 第 1.4 条、第 2.1.1 条第一款、第 7.7.7 条第十项的规定。 深圳证券交易所文件 深证上〔2024〕606 号 关于对山东沃华医药科技股份有限公司 及相关当事人给予通报批评处分的决定 当事人： 山东沃华医药科技股份有限公司，住所：山东省潍坊高新技 术产业开发区梨园街 3517 号； 赵彩霞，山东沃华医药科技股份有限公司副董事长 ...

Financial Performance - The net profit attributable to shareholders for the first half of 2024 is estimated to be 8.90 million yuan, a decrease of 76.08% to 64.52% compared to the same period last year, which was 37.20 million yuan [2]. - The net profit after deducting non-recurring gains and losses is projected to be 8.20 million yuan, down by 77.02% to 66.38% from 35.69 million yuan in the previous year [2]. - The basic earnings per share is expected to be 0.0154 yuan, a decline from 0.0645 yuan per share in the same period last year [2]. Product Performance - The core product, WoHua XinKeShu Pian, experienced a price reduction of approximately 39% due to winning a centralized procurement bid, leading to a decrease in sales revenue [4]. - The reduction in gross profit contribution has resulted in a decline in operating profit [5]. Forecast Accuracy - There are no significant uncertainties affecting the accuracy of this earnings forecast as of the announcement date [6]. - The above forecast data is preliminary and the specific financial data will be disclosed in the company's 2024 semi-annual report [7].

证券代码：002107 证券简称：沃华医药 公告编号：2024-021 山东沃华医药科技股份有限公司 山东沃华医药科技股份有限公司（以下简称公司）2023 年度权 益分派方案已获 2024 年 4 月 19 日召开的公司 2023 年度股东大会审 议通过，现将权益分派事宜公告如下： 一、股东大会审议通过权益分派方案情况 （一）2024 年 4 月 19 日，公司 2023 年度股东大会审议通过了 《公司 2023 年度利润分配预案》（以下简称利润分配方案）。根据该 方案，公司以现有总股本 577,209,600 股为基数，向全体股东每 10 股 派发现金红利 2.50 元（含税），共计派发现金红利 144,302,400.00 元 （含税），不送红股，不以公积金转增股本。上述利润分配预案披露 后至权益分派实施公告确定的股权登记日前，公司总股本发生变动的， 公司将按照现金分红总额不变的原则，相应调整分配比例。 （二）自利润分配方案披露至实施期间，公司股本总额未发生变 化，因此分配红利总金额及分配比例均不变。 （三）本次实施的权益分派方案与公司 2023 年度股东大会审议 通过的利润分配方案一致。 1 （四）本次 ...

索 引 号 bm56000001/2024-00004644 分 类 发布机构 发文日期 1713923820000 名 称 中国证券监督管理委员会山东监管局行政处罚决定书〔2024〕1号 文 号 〔2024〕1号 主 题 词 中国证券监督管理委员会山东监管局行政处罚决定书〔2024〕1号 〔2024〕1号 当事人：山东沃华医药科技股份有限公司（以下简称沃华医药），住所：山东省潍坊高新技术 产业开发区梨园街3517号。 赵彩霞，女，1969年11月出生，时任沃华医药副董事长、董事会秘书，住址：北京市朝阳区。 依据《中华人民共和国证券法》（以下简称《证券法》）的有关规定，我局对沃华医药涉嫌信 息披露违法违规行为进行了立案调查、审理，并依法向当事人告知了作出行政处罚的事实、理由、 依据及当事人依法享有的权利，当事人未提出陈述、申辩意见，也未要求听证。本案现已调查、审 理终结。 经查明，沃华医药存在以下违法事实： 沃华医药未按规定及时披露赵丙贤被采取留置措施的行为违反了《证券法》第八十条第一款、 第二款第十二项及《上市公司信息披露管理办法》（证监会令第182号）第二十二条第一款、第二 款第十七项的规定，构成《证券法 ...

Financial Performance - The company's revenue for Q1 2024 was CNY 215,317,031.37, representing a decrease of 8.49% compared to CNY 235,281,203.05 in the same period last year[5] - Net profit attributable to shareholders was CNY 9,667,223.23, down 62.01% from CNY 25,449,286.76 year-on-year[5] - The total profit for the period was CNY 10,773,028.68, down 57.33% from CNY 25,245,218.50 year-on-year[8] - The net profit for Q1 2024 was CNY 8,763,449.05, a decrease of 60.6% compared to CNY 22,231,890.00 in Q1 2023[18] - Operating profit for Q1 2024 was CNY 10,652,454.38, a decline of 57.8% compared to CNY 25,228,966.82 in Q1 2023[18] - The total comprehensive income for Q1 2024 was CNY 8,763,449.05, compared to CNY 22,231,890.00 in Q1 2023, reflecting a significant decrease[19] - The company reported a decrease in sales revenue from CNY 274,295,299.10 in Q1 2023 to CNY 254,036,073.89 in Q1 2024[20] Cash Flow and Liquidity - The net cash flow from operating activities increased by 74.60%, reaching CNY 54,487,330.32 compared to CNY 31,206,904.28 in the previous year[5] - Cash flow from operating activities for Q1 2024 was CNY 54,487,330.32, an increase of 74.5% from CNY 31,206,904.28 in Q1 2023[21] - The cash and cash equivalents at the end of Q1 2024 amounted to CNY 453,983,856.82, up from CNY 307,633,936.01 at the end of Q1 2023[21] - Cash and cash equivalents increased to RMB 456,686,925.02 from RMB 401,100,106.17 at the beginning of the quarter, reflecting a growth of 13.8%[13] - The cash outflow from operating activities in Q1 2024 was CNY 199,731,805.75, down from CNY 244,087,278.40 in Q1 2023[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,161,752,354.17, a 1.49% increase from CNY 1,144,706,388.58 at the end of the previous year[5] - Total assets as of March 31, 2024, were RMB 1,161,752,354.17, an increase from RMB 1,144,706,388.58 at the beginning of the quarter[16] - Total liabilities increased to RMB 319,510,871.57 from RMB 311,228,355.03, reflecting a rise of 2.1%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 40,099[10] - The largest shareholder, Beijing Zhongzheng Wanrong Investment Group Co., Ltd., holds 50.27% of the shares[10] Research and Development - Research and development expenses decreased by 45.21%, totaling CNY 8,520,639.75 compared to CNY 15,552,459.72 in the same period last year[8] - Research and development expenses decreased significantly to RMB 8,520,639.75, a reduction of 45.1% compared to RMB 15,552,459.72 in the previous year[17] Earnings Per Share - Basic and diluted earnings per share decreased by 50.00%, both at CNY 0.02 per share[5] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.02, down from CNY 0.04 in Q1 2023[19]